1. Home
  2. MNKD vs IBTA Comparison

MNKD vs IBTA Comparison

Compare MNKD & IBTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNKD
  • IBTA
  • Stock Information
  • Founded
  • MNKD 1991
  • IBTA 2011
  • Country
  • MNKD United States
  • IBTA United States
  • Employees
  • MNKD N/A
  • IBTA N/A
  • Industry
  • MNKD Biotechnology: Pharmaceutical Preparations
  • IBTA
  • Sector
  • MNKD Health Care
  • IBTA
  • Exchange
  • MNKD Nasdaq
  • IBTA Nasdaq
  • Market Cap
  • MNKD 1.1B
  • IBTA 892.4M
  • IPO Year
  • MNKD 2004
  • IBTA 2024
  • Fundamental
  • Price
  • MNKD $4.06
  • IBTA $40.05
  • Analyst Decision
  • MNKD Buy
  • IBTA Buy
  • Analyst Count
  • MNKD 6
  • IBTA 10
  • Target Price
  • MNKD $9.33
  • IBTA $74.60
  • AVG Volume (30 Days)
  • MNKD 3.0M
  • IBTA 369.9K
  • Earning Date
  • MNKD 08-06-2025
  • IBTA 08-13-2025
  • Dividend Yield
  • MNKD N/A
  • IBTA N/A
  • EPS Growth
  • MNKD 228.27
  • IBTA 24.66
  • EPS
  • MNKD 0.10
  • IBTA 2.03
  • Revenue
  • MNKD $297,595,000.00
  • IBTA $369,501,000.00
  • Revenue This Year
  • MNKD $13.72
  • IBTA $6.89
  • Revenue Next Year
  • MNKD $14.94
  • IBTA $15.55
  • P/E Ratio
  • MNKD $39.14
  • IBTA $19.69
  • Revenue Growth
  • MNKD 32.50
  • IBTA 7.20
  • 52 Week Low
  • MNKD $3.51
  • IBTA $31.40
  • 52 Week High
  • MNKD $7.63
  • IBTA $79.80
  • Technical
  • Relative Strength Index (RSI)
  • MNKD 55.84
  • IBTA N/A
  • Support Level
  • MNKD $3.74
  • IBTA N/A
  • Resistance Level
  • MNKD $4.13
  • IBTA N/A
  • Average True Range (ATR)
  • MNKD 0.14
  • IBTA 0.00
  • MACD
  • MNKD 0.05
  • IBTA 0.00
  • Stochastic Oscillator
  • MNKD 88.14
  • IBTA 0.00

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

About IBTA Ibotta Inc. Class A Common Stock

Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).

Share on Social Networks: